Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short- and long-term effects on mAb-producing CHO cell lines after cryopreservation.

Biotechnology progress·2018
Same author

Probing the importance of clonality: Single cell subcloning of clonally derived CHO cell lines yields widely diverse clones differing in growth, productivity, and product quality.

Biotechnology progress·2017
Same author

A Community-Based Partnership to Successfully Implement and Maintain a Breast Health Navigation Program.

Journal of community health·2015
Same author

A method for achieving reciprocity of funding in community-based participatory research.

Progress in community health partnerships : research, education, and action·2015
Same author

Lurasidone: a review of its use in adult patients with bipolar I depression.

CNS drugs·2015
Same author

Secukinumab: first global approval.

Drugs·2015
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rilpivirine.

Mark Sanford1

  • 1Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|February 24, 2012
PubMed
Summary
This summary is machine-generated.

Rilpivirine demonstrated non-inferior treatment response compared to efavirenz in HIV-1 patients. Rilpivirine was better tolerated, with fewer adverse events and lipid abnormalities.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Related Experiment Videos

Last Updated: May 24, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • HIV-1 infection requires combination antiretroviral therapy.
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key components of HIV treatment regimens.
  • Efavirenz has been a standard NNRTI, but newer agents are being evaluated for improved tolerability.

Purpose of the Study:

  • To compare the efficacy and safety of rilpivirine versus efavirenz in antiretroviral-naive adult patients with HIV-1 infection.
  • To assess treatment response rates and virological failure in patients receiving rilpivirine or efavirenz as part of combination therapy.

Main Methods:

  • Randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials.
  • Adult patients with HIV-1 infection, naive to antiretroviral therapy, were randomized.
  • Rilpivirine 25 mg once daily was compared with efavirenz 600 mg once daily, both with background nucleoside/nucleotide regimens.

Main Results:

  • Rilpivirine achieved non-inferior treatment response rates compared to efavirenz at 48 weeks (83-87% vs 83-84%).
  • Virological failure rates were generally higher with rilpivirine, particularly in patients with high baseline viral load (>100,000 copies/mL).
  • Rilpivirine was better tolerated, showing significantly fewer adverse events, discontinuations due to adverse events, and lipid abnormalities.

Conclusions:

  • Rilpivirine is a viable alternative to efavirenz for treatment-naive HIV-1 patients, offering comparable efficacy with improved tolerability.
  • The tolerability profile of rilpivirine, including fewer adverse events and lipid abnormalities, suggests a potential benefit for long-term HIV management.
  • Careful patient selection may be necessary, considering baseline viral load when choosing between rilpivirine and efavirenz.